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Chronic neuropathic pain is a debilitat-
ing condition that remains poorly treated
by current medications. Preclinical stud-
ies have indicated that cannabinoid recep-
tor agonists have analgesic efficacy in
neuropathic pain models, but this is
accompanied by undesirable side effects.
In recent years, novel strategies target-
ing the endogenous cannabinoid system
have emerged, which are being mooted as
safer alternatives. A recent clinical trial,
however, has demonstrated that a new
endocannabinoid modulator is ineffective
against osteoarthritic pain, despite exhibit-
ing efficacy during the preclinical stage.
Further basic and clinical work is needed
to resolve this disparity.
CANNABINOIDS AND CHRONIC PAIN
Chronic pain is a prevalent and costly
health care problem (Torrance et al.,
2006). A particularly persistent, severe and
debilitating form of chronic pain is neu-
ropathic pain. This syndrome manifests
following damage or dysfunction of the
peripheral nerves, spinal cord, or brain;
or can be caused by stroke, multiple
sclerosis or diabetes. Unfortunately, the
currently recommended pharmacological
treatments for neuropathic pain display
poor efficacy and illicit undesirable side
effects (Dworkin et al., 2010).
There is growing clinical evidence
indicating that the cannabis constituent,
9-tetrahydrocannabinol (THC), and
synthetic cannabinoid agonists have effi-
cacy in chronic pain states (Lynch and
Campbell, 2011). These human studies
are based upon substantial preclinical evi-
dence. A wide range of animal models of
neuropathic pain have demonstrated that
cannabinoid agonists reverse the common
symptoms of neuropathic pain, includ-
ing allodynia (to cool and innocuous
mechanical stimuli) and hyperalgesia (to
noxious thermal and mechanical stim-
uli) (Fox et al., 2001; Scott et al., 2004).
Unfortunately, this therapeutic interven-
tion is also associated with a number of
adverse effects, including sedation and
motor/cognitive impairment. Having said
this, the therapeutic window between the
desired and adverse effects of cannabinoids
has not been systematically examined.
Thus, it remains to be determined whether
cannabinoids can produce pain relief at
doses below the side effect threshold.
THE ENDOGENOUS CANNABINOID
SYSTEM—A TARGET FOR PAIN RELIEF
Since exogenous cannabinoid agonists act
globally throughout the central nervous
system to produce their effects, isolation
of the desired therapeutic action from the
unwanted side effects has remained a dif-
ficult challenge. To overcome this prob-
lem, alternative approaches at targeting
cannabinoid signaling have been explored
(Petrosino and Di Marzo, 2010; Piscitelli
and Di Marzo, 2012). Unlike exogenous
cannabinoids, endogenous ligands of the
cannabinoid system are synthesized in an
“on demand” fashion. This suggests spe-
cific, localized release of these transmitters
only in regions where their actions are per-
tinent. Thus, targeting endocannabinoids
may provide a more effective strategy in
relieving pain devoid of side effects.
Endocannabinoids are present in mul-
tiple pain-modulating regions throughout
the CNS, including the periaqueduc-
tal gray (PAG), rostral ventral medulla
(RVM) and spinal cord dorsal horn, where
their levels are enhanced by acute noci-
ceptive stimuli and stress (e.g., Walker
et al., 1999; Hohmann et al., 2005).
Interestingly, endocannabinoid levels
within these regions are also enhanced
in chronic pain models (Jhaveri et al.,
2007; Petrosino et al., 2007; Guindon
et al., 2013). Exogenous administration of
AEA or 2-AG produces THC-like effects,
but each elicits a distinct subset of the
total effects observed with exogenous
cannabinoid administration. Specifically,
in animal models, AEA administration
has been reported to produce antinocicep-
tion alone (Cravatt et al., 2001), or evoke
the full tetrad of cannabinoid agonist
effects—antinociception, hypothermia,
hypolocomotion and catalepsy (Smith
et al., 1994). By contrast, 2-AG adminis-
tration evokes only a subset of these effects
(Lichtman et al., 2002).While major endo-
cannabinoids, such as N-arachidonoyl
ethanolamide (anandamide or AEA) and
2-arachidonoyl glycerol (2-AG), act via
cannabinoid CB1 and CB2 receptors
in a manner similar to THC and syn-
thetic cannabinoid agonists, they may
also modulate nociception via non-
cannabinoid receptor targets. This is
particularly the case for anandamide,
which has actions on transient receptor
potential vanilloid 1 (TRPV1) and per-
oxisome proliferator-activated receptor-α
(PPAR-α), both of which are cellular tar-
gets implicated in nociception (Jhaveri
et al., 2007; Di Marzo and De Petrocellis,
2012).
www.frontiersin.org March 2014 | Volume 5 | Article 28 | 1
Lau and Vaughan Endocannabinoids and neuropathic pain
The actions of endocannabinoids are
tightly regulated by enzymatic degrada-
tion. In particular, AEA is degraded via
fatty acid amide hydrolase (FAAH), and 2-
AG via monoacylglycerol lipase (MAGL)
(Cravatt et al., 1996; Dinh et al., 2002).
In addition, two serine hydrolases, ABHD6
and ABHD12, have recently been impli-
cated in the hydrolysis of 2-AG (Blankman
et al., 2007; Savinainen et al., 2012); how-
ever, their presence in pain pathways has
yet to be confirmed. In recent years, a
number of pharmacological tools have
been developed which selectively inhibit
FAAH and MAGL (Kathuria et al., 2003;
Long et al., 2009a; Ahn et al., 2011).
Inhibition of these degradative enzymes
is thought to specifically enhance endo-
cannabinoids where they are produced
on demand, resulting in more localized
receptor activation compared to globally
acting exogenous agonists. Considerable
attention has been focused on developing
degradation inhibitors to indirectly target
the endocannabinoid system.
NOVEL ENDOCANNABINOID
MODULATORS—FAAH AND MAGL
INHIBITORS
A number of groups have demonstrated
that selective FAAH inhibitors, such as
URB597, OL-135, PF-3845, PF- 04457845
and ST-4070 alleviate the mechanical and
cold allodynia induced in a range of ani-
mal models of chronic pain (Russo et al.,
2007; Kinsey et al., 2009, 2010; Ahn et al.,
2011; Caprioli et al., 2012; Guindon et al.,
2013). Although it has not been exam-
ined systematically, this analgesic effect
occurs at doses that do not elicit the tetrad
of cannabinoid-induced side effects. The
evidence in support of FAAH inhibitors,
however, is not unanimous. For exam-
ple, our group originally found that sys-
temic administration of URB597 had no
effect on mechanical allodynia in the par-
tial nerve ligation (PNL) model of neu-
ropathic pain (Jayamanne et al., 2006),
despite the synthetic analog of THC, HU-
210 abolishing allodynia in the same study.
The contrasting findings between these
studies might be due to a number of fac-
tors. Firstly, the above studies examined a
range of different neuropathic pain mod-
els. Indeed, we have observed that, unlike
the PNL model, URB597 reduces allody-
nia (albeit at higher doses) in the sciatic
nerve chronic constriction injury (CCI)
model (unpublished data). Secondly, the
wide range of different FAAH inhibitor
compounds administered at varying doses
may account for the contrasting efficacy
on allodynia, particularly since some of
compounds in question did not display
clear dose dependence in pain assays (e.g.,
Ahn et al., 2011). Thirdly, depending on
the acute or chronic pain assay examined,
it is possible that endocannabinoid acti-
vation of CB1 and TRPV1 receptors may
have opposing effects on nociception, thus
confounding the observed results (Maione
et al., 2006). Together, these studies suggest
that FAAH inhibitors may be efficacious
for neuropathic pain, but more systematic
studies need to be conducted to confirm
their therapeutic potential.
Compared to FAAH inhibitors, there
have been relatively fewer studies exam-
ining MAGL inhibitors in pain models.
This is mainly due to their later iden-
tification and development. Nevertheless,
systemic administration of the MAGL
inhibitors, JZL-184 and KML-29, have
been shown to alleviate allodynia in cer-
tain neuropathic pain models, without
eliciting the full tetrad of cannabinoid-
induced effects (Kinsey et al., 2009, 2010,
2013; Schlosburg et al., 2010; Guindon
et al., 2013; Ignatowska-Jankowska et al.,
2013). Interestingly, while analgesic effi-
cacy is maintained during chronic admin-
istration of low doses of JZL184, tolerance
has been shown to develop at higher doses
(Kinsey et al., 2013). This latter observa-
tion is clinically relevant, since conditions
like chronic pain often require long-term
drug treatment.
THERAPEUTIC POTENTIAL OF
ENDOCANNABINOID MODULATORS
In a recent clinical trial, the FAAH
inhibitor, PF-04457845 was found inef-
fective in patients with osteoarthritic pain
(Huggins et al., 2012). This was despite a
clear abolition of FAAH activity and eleva-
tion in plasma AEA levels in almost all sub-
jects tested. This finding directly contrasts
those observed by the same group in an
animal model of inflammatory and non-
inflammatory pain, in which PF-04457845
produced a potent antinociceptive effect
(Ahn et al., 2011).While the reason for this
contrasting efficacy between humans and
animals is not clear, it should be noted that
the former study was likely confounded by
a number of human factors (Di Marzo,
2012). Furthermore, the study examined
only an osteoarthritic model of pain. Thus,
the utility of FAAH inhibitors in the treat-
ment of neuropathic pain remains to be
explored.
SYNERGISTIC/ANTAGONISTIC
INTERACTIONS OF
ENDOCANNABINOIDS
In chronic pain states, patients often
receive drugs in combination. The aim
of this approach is to produce greater or
potentially synergistic analgesia at lower
drug doses. Indeed, there is some clini-
cal evidence in favour of the combined
use of cannabinoid and opioid agonists
in chronic pain patients, although synergy
has yet to be established (Abrams et al.,
2011).
This combinatorial approach might
also be applied to the endocannabinoid
modulators described above. One promis-
ing idea would be to inhibit both FAAH
andMAGL (Pertwee, 2013). In this regard,
dual inhibitors of both FAAH and MAGL
have recently been developed (Long et al.,
2009b; Ramesh et al., 2013), although
they remain to be systematically tested in
chronic pain models. Because FAAH and
MAGL act via distinct pathways to degrade
AEA and 2-AG, dual inhibition of these
degradative enzymes should boost levels
of both endocannabinoids. It is unknown
whether this will produce an additive or
synergistic effect. Therefore, it would be
interesting to observe the effect of dual
FAAH/MAGL inhibition in neuropathic
pain models, particularly in terms of their
efficacy and therapeutic window relative to
FAAH or MAGL inhibition.
It should be noted that whilst the
antinociceptive effect of MAGL inhibitors
is specifically abolished by CB1 recep-
tor antagonism or knockout (Kinsey
et al., 2009, 2010), the effect by FAAH
inhibitors is not only abolished/reduced
by CB1 and CB2 receptor blockade (Russo
et al., 2007; Kinsey et al., 2009, 2010),
but also antagonism of TRPV1 receptors
and PPAR-α (Caprioli et al., 2012). Since
TRPV1 and PPAR-α are predominantly
pro-nociceptive targets, this suggests
FAAH inhibition may produce compet-
ing, opposing actions on antinociception.
Thus, it would be interesting to examine
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the effect of a FAAH inhibitor in com-
bination with a TRPV1 antagonist. In
this regard, the endocannabinoid-related
agent, N-arachidonoyl-serotonin is a dual
FAAH/TRPV1 inhibitor found to be highly
effective in neuropathic pain models
(De Novellis et al., 2011). In addition to
pro-nociceptive targets, FAAH inhibition
has been demonstrated to produce pro-
nociceptive metabolites by diverting AEA
breakdown through other metabolic path-
ways, such as cyclooxygenase-2 (COX-2)
(Gatta et al., 2012). Hence, another poten-
tial interaction worth examining is dual
inhibition of FAAH and COX-2. Such
an approach may also lead to enhanced
analgesic efficacy (Fowler et al., 2009).
Together, the above studies impor-
tantly highlight that while some endo-
cannabinoid pathways act synergistically,
others may act antagonistically to reduce
antinociception. Therefore, prizing apart
these subcellular pathways may provide a
means to further improve the safety and
efficacy of endocannabinoid modulators.
FUTURE DIRECTIONS
While the lack of efficacy of a FAAH
inhibitor in a recent clinical trial is disap-
pointing, there are alternative approaches
targeting the endocannabinoid system
which may still be of promise. These need
to be first addressed in animal studies
before proceeding with further clinical tri-
als. In particular, the efficacy of the highly
specific, individual MAGL inhibitors and
the recently developed, dual FAAH/MAGL
inhibitors need to be explored in neuro-
pathic pain models. Furthermore, the use
of these degradation inhibitors in com-
bination with agents that act on related
targets should be investigated (Di Marzo,
2012). Both drug efficacy and side-effect
profiles need to be examined systemati-
cally. This may eventually lead to an effec-
tive pharmacotherapy to treat the prob-
lematic condition of neuropathic pain.
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